



EDITORIAL

Meet the Acta Oncologica editorial board

Mef Nilbert^{a,b,c}

^aDanish Cancer Society Research Center, Copenhagen, Denmark; ^bClinical Research Center, Hvidovre University Hospital, Copenhagen University, Copenhagen, Denmark; ^cDepartment of Oncology, Institute of Clinical Sciences, Lund University, Lund, Sweden

ARTICLE HISTORY Received 25 November 2019; Accepted 26 November 2019

As every journal Acta Oncologica depends upon our Associate Editors for success. It is with great pleasure that I introduce our new Editorial Board.

Acta Oncologica publishes a breath of scientific articles in oncology - from genetic epidemiology to radiation therapy and from treatment predictive biomarkers to survivorship perspectives. The journal is the scientific periodical of the Nordic Societies of Oncology and the Nordic Association of Medical Physics [1–3]. Leading clinical cancer researchers from the Nordic countries bring various expertise in cancer research and clinical oncology, methodologic skills and statistical knowledge to the Editorial board.

We are proud of the direction that the journal has taken with an increasing and improving number of submissions to the current 1000 submissions annually. This allows us publication of relevant and timely content and is reflected in an increasing impact factor that is at present 3.3 [4,5]. Acta Oncologica offers early online availability and free open access after 6 months. Our print version has been terminated and all content back to the 1960'ies is available online.

Our ten Associate Editors work to expedite editorial handling and to grant authors rapid, authoritative and fair evaluations (Figure 1). The Associate Editors cover complementary areas and have manuscripts assigned to them based on topic. They also support in the review process and ensure that decisions about publication are shared between reviewers and editors. The editorial board meets regularly to evaluate services and performance, discuss overall goals and trends, prioritise special issues and initiatives and advise on strategy to respond to the widening horizons in modern oncology [6,7].

Cancer epidemiology

Giske Ursin is the Director of the Cancer Registry of Norway. She is also a Professor II at the Department of Nutrition, Institute of Basic Medical Sciences, at the University of Oslo and Professor Emeritae at the University of Southern California (USC). She is an expert in cancer epidemiology with extensive experience in population-based studies as well as experience in cancer surveillance. Her editorial

responsibilities encompass cancer epidemiology, including causes, prevention and control.

Karin E. Smedby is a physician and research group leader at the Karolinska Institutet in Stockholm, Sweden. Her specific research interests relate to cancer epidemiology and hematology with a focus on lymphoma. She serves as a co-editor for manuscripts reporting population and cohort studies, early cancer detection and outcome.

Radiobiology, radiophysics and radiotherapy

Jens Overgaard is Professor of Oncology at the University of Aarhus in Denmark. His research is focussed at experimental and clinical radiotherapy and establishment of innovative treatments for head and neck cancer and breast cancer. In Acta Oncologica he is responsible for the BIGART symposium on radiotherapy and holds editorial responsibilities for study protocols [8].

Mikko Tenhunen is Chief physicist and an Honorary Professor at Helsinki University Central Hospital in Finland. His research is focussed at radiophysics with expert skills in dosimetry and radiotherapy. His editorial responsibilities relate to radiophysics and radiotherapy.

Morten Høyer is Professor of Oncology at the University of Aarhus in Denmark. He is an expert in radiotherapy with specific interest in immuno-radiotherapy and radiotherapy of brain tumours, liver cancer, prostate cancer and paediatric cancers. He also serves as the head of the Danish Centre for Particle Therapy. His editorial responsibilities include radiobiology, radiotherapy and indications for as well as side-effects from these treatment modalities.

Medical oncology and immunotherapy

Olav Dahl is a Professor of Oncology at the University of Bergen in Norway. He is a distinguished translational researcher with specific interests in testicular and prostate cancer, gastrointestinal cancers, and clinical use of chemotherapy and radiation. He serves as an editor primarily for manuscripts within clinical and medical oncology and immunotherapy.



Figure 1. Acta Oncologica editors.

Micaela Hernberg is a senior consultant at the Helsinki University Hospital in Finland. She has broad expertise in medical oncology and clinical trials and serves as a co-editor with responsibilities in clinical oncology and immuno-oncology.

Marianne Guren is a senior consultant and researcher at the Oslo University Hospital, Norway. Her clinical responsibilities and research is focussed at gastrointestinal cancer with clinical and translational studies. She serves as an editor for manuscripts in medical oncology, radiotherapy and patient perspectives.

Rehabilitation and late side effects

Christoffer Johansen is a Professor of Cancer Survivorship at the University of Copenhagen in Denmark, currently affiliated with the Oncology clinic at Rigshospitalet. His areas of expertise, for which he serve as a co-editor, relate to psychological and social aspects of cancer, late effects, rehabilitation, palliative care and survivorship perspectives.

Statistics

Christian Dehlendorff is a statistician and group leader at the Danish Cancer Society Research Centre in Copenhagen.

He serves as statistical editor with specific focus on study design, choice of statistical methods and assessment of results.

Acta Oncologica is extremely grateful for the contributions from our Editors. Together we will continue our work to further develop Acta Oncologica as a preferred choice for scientific communication in oncology. In this work we would also like to thank our large team of dedicated reviewers. You are the backbone of Acta Oncologica.

Disclosure statement

No potential conflict of interest was reported by the author.

References

- [1] Glimelius B. Oncology in the Nordic countries-the role of Acta Oncologica? Acta Oncol. 2002;41(1):3–5.
- [2] Glimelius B. The 50-year anniversary of Acta Oncologica. Acta Oncol. 2014;53(1):1–2.
- [3] Muren LP, Glimelius B. And they lived happily ever after... The marriage of Nordic Associations for Clinical Physics and Acta Oncologica. Acta Oncol. 2011;50(6):835–837.

- [4] Glimelius B. More than 1000 new manuscripts in 2017. *Acta Oncol.* 2018;57(2):174–175.
- [5] Glimelius B. Forty-five years in oncology, 25 years with *Acta Oncologica*. *Acta Oncol.* 2018;57(12):1593–1598.
- [6] Johansen C, Dalton SO. Survivorship in new harbors. *Acta Oncol.* 2017;56(2):119–122.
- [7] Heymach J, Krilov L, Baxter N, et al. Clinical cancer advanced 2018: annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol.* 2018;36(10):1020–1044.
- [8] Grau C, Hoyer M, Rugaard Poulsen P, et al. Rethink radiotherapy – BIGART 2917. *Acta Oncol.* 2017;56(11):1341–1352.